Media - Abzena


MHC Associated Peptide Proteomics

Case Study MAPPs for Vaccine Design To identify MHC class I presented antigens derived from influenza strain H1N1, two[...]




5 November 2018

This “must-attend” event is Europe’s largest life science partnering conference. BIO-Europe attracts a[...] Read more

Immunogenicity & Bioassay Summit

22 October 2018

Now in its 10th year, CHI’s Immunogenicity & Bioassay Summit will examine the challenges currently facing the[...] Read more


Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids

Natural products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs) have utilized[...] Read more


Abzena announces a research and licence agreement with Tmunity Therapeutics, a T cell engineering company

Cambridge, UK, 19 September 2018 – Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and[...] Read more

Faron Pharmaceuticals Ltd announces that it has filed a Clinical Trial Application (CTA)

Faron Pharmaceuticals Ltd today announced that it has filed a Clinical Trial Application (CTA) for Clevegen®, an ABZENA[...] Read more


We’re changing the way we brand our businesses

To provide our Partners with a single identity for the services and technologies offered across Antitope, PacificGMP,[...] Read more

Interested in our services? Get In Touch